Autres langues NewAmsterdam Pharma Company N.V. Börse Stuttgart

Actions

KH6

NL00150012L7

Recherche biotechnologique et médicale

Temps réel estimé Tradegate 09:30:37 09/10/2026			Varia. 5j.	Varia. 1 janv.
18,95 ^EUR	+0,23%		-11,58%	-35,70%

05/10	NewAmsterdam : l’analyse intermédiaire de PREVAIL présente un risque « considérable », selon RBC	MT
05/10	Frazier Lifesciences Acquisition Corporation : RBC Capital Markets favorable sur le dossier	ZM

Autres langues

05/10	NewAmsterdam PREVAIL Interim Faces 'Considerable' Risk, RBC Says
02/10	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29/09	NewAmsterdam Pharma Doses First Participant in Phase 2b Trial for Preclinical Alzheimer's Disease
29/09	NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease
29/09	NewAmsterdam Pharma Company N.V. Doses First Participant In Phase 2b SPINOZA Trial Evaluating Obicetrapib In Preclinical Alzheimer?s Disease
22/09	European Commission Approves Obicetrapib for Primary Hypercholesterolemia
21/09	NewAmsterdam Pharma Gets EU Approval for Ubeslo, Evlarco
21/09	NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
21/09	NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
21/09	Newamsterdam Pharma Company N.V. and Menarini Group Receive European Commission Approval for Ubeslo and Evlarco
04/09	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
03/09	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/09	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
26/08	NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
26/08	NewAmsterdam Pharma Presents Data From Obicetrapib Development Program At European Society Of Cardiology Congress 2026
14/08	Newamsterdam Pharma Company N.V. Announces Executive Changes
06/08	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/08	NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
05/08	Earnings Flash (NAMS) NewAmsterdam Pharma Company N.V. Reports Q2 Revenue $3.7M, vs. FactSet Est of $1.9M
05/08	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
29/07	NewAmsterdam Pharma to Host Investor Day on August 5, 2026
27/07	NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo and Evlarco
24/07	NewAmsterdam Pharma Says EMA Committee Recommends Approval of Cholesterol Treatments
24/07	Newamsterdam Pharma Company N.V. and Menarini Group Receives Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
24/07	NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)